Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre Armand

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Bulletin Du Cancer|January 13, 2004
[Focus on cellular pharmacology of docetaxel]Jean-Pierre Armand
Bulletin Du Cancer|July 24, 2002
[The multifaceted large stones of the president of the French Cancer Society]Jean-Pierre Armand
Bulletin Du Cancer|February 11, 2004
[Therapeutic efficacy of treatments aimed at the EGF receptor]Jean-Pierre Armand, Gérard Milano
Chinese Clinical Oncology|January 6, 2016
PrefaceJean-Pierre Armand, Liya Ju
Bulletin Du Cancer|February 7, 2004
[Anti-epidermal growth factor receptor treatment: a new paradigm for conducting therapeutic trials]Michel Marty, Naima Bedairia, Jean-Pierre Armand
Future Oncology (London, England)|November 8, 2012
Early evaluation of targeted drugs using dynamic contrast-enhanced ultrasonography for personalized medicineNathalie Lassau, David Cosgrove, Jean-Pierre Armand
Bulletin Du Cancer|September 13, 2007
[Oral drugs inhibiting the VEGF pathway]Stanislas Ropert, Olivier Mir, Jean-Pierre Armand
Current Opinion in Oncology|April 8, 2004
Optimal management of nasopharyngeal carcinomaSandrine Faivre, François Janot, Jean-Pierre Armand
Bulletin Du Cancer|February 4, 2006
[PI3K-AKT-mTOR pathway inhibitors]Alexis Cortot, Jean-Pierre Armand, Jean-Charles Soria
Onkologie|October 6, 2005
[Inhibition of angiogenesis by proteins, peptides and "small molecules"]Gordon Jayson, Jean-Pierre Armand, Wolfgang E Berdel
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|January 13, 2004
[Focus on cellular pharmacology of docetaxel]Jean-Pierre Armand
Bulletin Du Cancer|July 24, 2002
[The multifaceted large stones of the president of the French Cancer Society]Jean-Pierre Armand
Bulletin Du Cancer|February 11, 2004
[Therapeutic efficacy of treatments aimed at the EGF receptor]Jean-Pierre Armand, Gérard Milano
Chinese Clinical Oncology|January 6, 2016
PrefaceJean-Pierre Armand, Liya Ju
Bulletin Du Cancer|February 7, 2004
[Anti-epidermal growth factor receptor treatment: a new paradigm for conducting therapeutic trials]Michel Marty, Naima Bedairia, Jean-Pierre Armand
Future Oncology (London, England)|November 8, 2012
Early evaluation of targeted drugs using dynamic contrast-enhanced ultrasonography for personalized medicineNathalie Lassau, David Cosgrove, Jean-Pierre Armand
Bulletin Du Cancer|September 13, 2007
[Oral drugs inhibiting the VEGF pathway]Stanislas Ropert, Olivier Mir, Jean-Pierre Armand
Current Opinion in Oncology|April 8, 2004
Optimal management of nasopharyngeal carcinomaSandrine Faivre, François Janot, Jean-Pierre Armand
Bulletin Du Cancer|February 4, 2006
[PI3K-AKT-mTOR pathway inhibitors]Alexis Cortot, Jean-Pierre Armand, Jean-Charles Soria
Onkologie|October 6, 2005
[Inhibition of angiogenesis by proteins, peptides and "small molecules"]Gordon Jayson, Jean-Pierre Armand, Wolfgang E Berdel
Pageof 6